|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Medullary thyroid carcinoma (MTC) is responsible for 13.4% of the total deaths attributable to thyroid cancer in human beings and research on MTC over the last 40 years has identified the RET proto-oncogene as a very relevant component of development of both sporadic and hereditary MTC.
|
18502338 |
2008 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We designed the present study to evaluate in a single laboratory, using the same methodologies, the pattern of RET/PTC activation in thyroid tumors from different groups of patients (exposed or not exposed to radiation, children or adults, with benign or malignant tumors) in relationship to the above mentioned variables.
|
11443191 |
2001 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These targets include the proto-oncogenes BRAF and RET, known to be common mutations in thyroid cancer; vascular endothelial growth factor receptor and platelet-derived growth factor receptor, associated with angiogenesis; and the sodium-iodide symporter, with the aim of restoring its expression and hence radioactive iodine uptake.
|
20142332 |
2010 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The posttest probability of thyroid cancer was 100% for nodules positive for BRAF or RET-PTC, 70% for RAS or PAX8-PPARG, and 88% for molecular cytology overall.
|
24811481 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Oncogenic proteins such as Ret/PTC, Ras and BRAF can induce NF-kappaB activation making it an important change in thyroid cancer.
|
17891249 |
2007 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings in a cellular context relevant to the pathological function of RET oncogenes support the role of Ret oncoproteins as useful targets for therapeutic intervention, and suggest RPI-1 as a promising candidate for preclinical development in the treatment of thyroid tumors expressing RET oncogenes.
|
12943231 |
2003 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
|
9861322 |
1998 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants.
|
26652860 |
2016 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
CCDC6 was originally identified in chimeric genes as caused by chromosomal translocation involving the RET protooncogene in some thyroid tumors.
|
23145146 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Thyroid cancer is frequently associated with the oncogenic conversion of the RET receptor tyrosine kinase.
|
16778204 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Targeting RET for thyroid cancer therapy.
|
19028457 |
2009 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
It was originally identified in chimeric genes caused by chromosomal translocation involving RET proto-oncogene in some thyroid tumors.
|
30909182 |
2019 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The relatively low prevalence of RET activation in PDCs argues against a major role for RET/PTC in the progression from well to poorly differentiated thyroid tumor phenotypes.
|
11788678 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, an extensive molecular analysis that included all codons was prompted by the diagnosis of thyroid neoplasm in a patient's sister, and identified the rare intracellular RET p.Ser891Ala mutation.
|
23295303 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since fine-needle aspiration biopsy (FNAB) is an important component of the preoperative management of patients with thyroid tumors, we developed a rapid (20-min) method that enables extraction of DNA from FNABs for RET mutation analysis.
|
9824378 |
1998 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Analysis by a reverse transcriptase-polymerase chain reaction method showed that the ret rearrangement-positive tumor contained the PTC/retTPC chimeric transcript, which was reported to be found specifically in thyroid tumors and adenomatous goiter.
|
1381340 |
1992 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Rearrangements of the RET receptor tyrosine kinase gene generating RET/PTC oncogenes are specific to papillary thyroid carcinoma (PTC), the most frequent thyroid tumor.
|
16203990 |
2005 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here we describe the first evidence of ret proto-oncogene rearrangement of thyroid cancer tissues around the site.
|
10551507 |
1999 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We did a comprehensive screen for 548 known and putative fusion genes in 27 samples of thyroid tumors and three positive controls-one thyroid cancer cell line (TPC-1) and two PTCs with known CCDC6-RET (alias RET/PTC1) fusion gene, using this microarray.
|
22961909 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A G691S RET polymorphism was present with a higher frequency in radiation-induced epithelial thyroid tumours (55%) than in sporadic tumours (20%) and in control normal thyroid tissues (15%).
|
12085189 |
2002 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The catalytic domain of RET can be used also for X-ray diffraction to obtain information about the three-dimensional structure, necessary for a rational design of selective inhibitors: it represents an important tool to understand the molecular mechanisms causing thyroid cancer and to care it.
|
16490247 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
ZD 6474 has shown promising activity in preclinical models against RET kinase, and its contemporary inhibition of vascular endothelial growth factor and epidermal growth factor pathways renders it a very attractive drug for clinical trials in thyroid cancer.
|
16940797 |
2006 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Several types of rearrangement known to occur in thyroid cancer, including RET/PTC, NTRK1 and BRAF/AKAP9, are more common in radiation-associated thyroid tumors and RET/PTC can be induced experimentally by exposing human thyroid cells to ionizing radiation.
|
19766698 |
2010 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases.
|
22584703 |
2012 |